Glenmark Pharmaceuticals Receives US FDA Compliance Report for Monroe Manufacturing Facility

Glenmark Pharmaceuticals has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its formulations manufacturing facility located in Monroe, North Carolina. The EIR signifies the completion of an inspection conducted by the regulatory agency, indicating compliance with applicable requirements.

The Monroe facility underwent a thorough review by the US FDA, which evaluates adherence to Good Manufacturing Practices (GMP) and other regulatory standards. The issuance of the EIR confirms that Glenmark’s operations at this site meet these standards. This development follows routine inspections conducted by the agency to ensure pharmaceutical manufacturing facilities maintain quality and safety protocols.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

Related posts:

U.S. Solicitor General Advises Supreme Court Not to Review Oklahoma PBM Regulation Law Statins Linked to 39 Percent Reduction in Sepsis Mortality Risk White House Considers Restrictions on China-Developed Treatments as Pfizer Reports Strong Immune Response to Updated COVID-19 Vaccine Study Explores Optimized On-Farm Trials to Enhance Micronutrient Content in Grain Crops

Author

GOAI